Drugs / Sarcosine
Sarcosine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT00977353 | Apr 2009 → Jul 2011 | major depressive disorder | China Medical University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00276263 | Aug 2006 → Jun 2009 | schizophrenia | Herzog Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT00491569 | Jan 2005 → Dec 2006 | schizophrenia | China Medical University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00328276 | Dec 2004 → Dec 2005 | schizophrenia | China Medical University Hospital | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT04975100 | Aug 2021 → Apr 2023 | major depressive disorder | All India Institute of Medical Sciences, Bhubaneswar | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01047592 Comparator | Mar 2009 → Dec 2013 | schizophrenia | Chang-Hua Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sarcosine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04975100 ↗ |
| Known as | Methylamino-acetic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL304383 ↗ |
| Known as | N-methylglycine | “For example, sarcosine (N-methylglycine, a glycine transporter I inhibitor) showed therapeutic effects not only in chronically stable patients but also in acutely exacerbated...” NCT00328276 ↗4“Sarcosine (N-Methyl Glycine), an endogenous amino acid with NMDA receptor function enhancing property, is usually used as a dietary supplement or nutraceutical.” NCT04975100 ↗ “such as sarcosine (N-methylglycine), have been used as adjunctive therapy of schizophrenia.” NCT00977353 ↗ “sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia” PMID 19887019 ↗ Nov 2009 “Sarcosine (N-methylglycine)” NCT00276263 ↗ |
| Action | Inhibit | “glycine transport inhibitor sarcosine” NCT00276263 ↗ |
| Modality | Other / unclassified | “Sarcosine is a natural amino acid” NCT00276263 ↗ |
| Route | Oral | “500-1500 mg/day, oral, for 6 weeks” NCT00977353 ↗ |